Detect V / CHEVENDO (Chemo vs. Endo)
NCT02344472 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 271
Last updated 2024-06-04
Summary
Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.
Conditions
Interventions
- DRUG
-
HER2 targeted Therapy
- DRUG
-
HER2 targeted Therapy
- DRUG
-
Chemotherapy
- DRUG
-
Chemotherapy
- DRUG
-
Chemotherapy
- DRUG
-
Chemotherapy
- DRUG
-
Exemestane
endocrine therapy
- DRUG
-
endocrine therapy
- DRUG
-
Anastrozole
endocrine therapy
- DRUG
-
endocrine therapy
- DRUG
-
CDK 4/6 inhibitor
- DRUG
-
chemotherapy
- DRUG
-
eribulin
chemotherapy
- DRUG
-
leuprorelin
endocrine therapy
- DRUG
-
goserelin
endocrine therapy
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY - collaborator INDUSTRY
-
Eisai GmbH
collaborator INDUSTRY -
Celgene Corporation
collaborator INDUSTRY -
Prof. Wolfgang Janni
lead OTHER
Principal Investigators
-
Jens Huober, MD PhD · Studienzentrale Dpt. Gyn/OB University Ulm
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-30
- Primary Completion
- 2025-01-31
- Completion
- 2025-01-31
Countries
- Germany
Study Locations
More Related Trials
-
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)
NCT03084757 ·Status: COMPLETED ·Phase: NA
-
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
NCT02035813 ·Status: COMPLETED ·Phase: PHASE2
-
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
NCT05572645 ·Status: COMPLETED
-
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3
-
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
NCT03523572 ·Status: COMPLETED ·Phase: PHASE1
-
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239 ·Status: RECRUITING ·Phase: PHASE3
-
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
NCT05880927 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612 ·Status: RECRUITING
-
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
NCT06144944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
NCT05020964 ·Status: UNKNOWN ·Phase: PHASE2
-
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
NCT03084237 ·Status: COMPLETED ·Phase: PHASE3
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
NCT01576666 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
NCT05328440 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04254263 ·Status: RECRUITING ·Phase: PHASE3
-
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03238196 ·Status: COMPLETED ·Phase: PHASE1
-
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
NCT02999672 ·Status: COMPLETED ·Phase: PHASE2
-
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
NCT04152057 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
NCT06202261 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060 ·Status: RECRUITING ·Phase: PHASE3